© 2024 Deurali-Janta Pharmaceuticals Pvt. Ltd. All rights reserved.
Coronavirus disease (COVID-19) is an infectious disease caused by a newly discovered coronavirus. Most people infected with the COVID-19 virus will experience mild to moderate respiratory illness and recover without requiring special treatment. Older people, and those with underlying medical problems like cardiovascular disease, diabetes, chronic respiratory disease, and cancer are more likely to develop serious illness. The best way to prevent and slow down transmission is to be well informed about the COVID-19 virus, the disease it causes and how it spreads. Protect yourself and others from infection by washing your hands or using an alcohol based rub frequently and not touching your face. The COVID-19 virus spreads primarily through droplets of saliva or discharge from the nose when an infected person coughs or sneezes, so it’s important that you also practice respiratory etiquette (for example, by coughing into a flexed elbow).https://www.who.int/emergencies/diseases/novel-coronavirus-2019
The first case of COVID-19 was reported in January 23, 2020 in Nepal (Travel History: China).
The first case of COVID-19 was reported in January 23, 2020 in Nepal (Travel History: China). Country went through 2 phases of lockdown since March, 2020. Till April 4, 2020 Nepal confirmed 8 imported cases, no death record and 1 local transmission case reported. Within 11 month time COVID-19 cases have increased substantially across the nation; Terai areas remained worse hit in early months of pandemic; Cases in Kathmandu are on rise.
CloseDeurali-Janta produced Ethanol based (75%) Hand Sanitizer purely for CSR purpose.
Deurali-Janta donated 100K Hydroxychloroquine Tablets (HYQUIN 200), as a possible treatment, to the Ministry of Health for those affected by the COVID-19 Pandemic in the early phase of the crisis.Deurali-Janta produced Ethanol based (75%) Hand Sanitizer purely for CSR purpose. Free distribution of DJ-Sanitizer is being done to Healthcare professionals on regular basis across the country. Deurali-Janta came up with “CARE FOR HEROES” initiative. We distributed Care Packages to front line Healthcare workers (Doctors, Nurses, and Pharmacists) countrywide. The package included KN95 face mask, hand sanitizer (DJ-Sanitizer), hand wash and tissue boxes. Deurali-Janta started social media campaign on awareness of COVID-19 and possible measures to avoid getting infected with this contagious disease. During these atypical times of COVID-19 Pandemic Crisis, Deurali-Janta is the first National Pharmaceutical Company to attain manufacturing License for FAVIPIRAVIR 200 mg Tablet (FAVIR 200). The drug is the recommended therapy in many countries for mild to moderate cases of COVID-19. FAVIPIRAVIR is the part of COVID-19 treatment protocol approved by NMC (Nepal Medical Council). In the history of Nepal, Deurali-Janta Pharmaceuticals is the first and only company to conduct phase III clinical trial of medicinal product (Favipiravir) is association of NHRS and MoH of Nepal.
CloseFor better preparedness of our corporate and factory premises, Deurali-Janta established a COVID-19 Emergency Response Committee.
For better preparedness of our corporate and factory premises, Deurali-Janta established a COVID-19 Emergency Response Committee. Following in-house activities have been performed for the safety of our employees;COVID-19 Symptoms Checklist (WHO & DJPL in-house specs.) for individual employee’s health analysis.Entry Exit Protocol for Corporate & Factory premises.COVID-19 Corporate Protocol.Corporate & Factory Premises Canteens’ Operation Protocol.COVID-19 related Instruction boards display at Corporate & Factory Premises.Routine Health Check-Ups of Employees at Factory Premises.Employees’ Awareness Programs on COVID-19 at Factory & Corporate premises.Self-Isolation Guidelines/ SOP for DJPL Staff. COVID-19 related Instruction posters display in Quarantine Areas for residential purpose at factory premises & Staff hostel.In-house Treatment Protocol for COVID-19 (Ref. NMC/ WHO/ USA and Bangladesh Guidelines).Installation of Hand Sanitizer Stands on various places in Factory & Corporate premises.PPE provision to the employees on high risk of exposure to Coronavirus.Quarantine facility provided to Factory employees on high risk of exposure to Coronavirus.
CloseLockdown.Operating 24 hour health desk facility.COVID-19 Quarantine Operation and Management Guideline- 2076, PPE use guideline for COVID-19
Lockdown.Operating 24 hour health desk facility.COVID-19 Quarantine Operation and Management Guideline- 2076, PPE use guideline for COVID-19, COVID-19 clinical management guideline.COVID-19 test facility from different designated hospitals and treatment provision from different hospitals in terms of the coverage.Logistic supply in all provinces.Consensus on SAARC relief trust.Media mobilization (Press Conferences, Mobile Ring-back Tone, Apps.).Distribution of relief packages.
CloseOpen border with india. Sufficient PPE availability.Sufficient Ventilator savailability. Sufficient Ventilators availability. Quarantince & Isolation facilities.
Deurali-Janta is the first National Pharmaceutical Company to attain manufacturing License for FAVIPIRAVIR 200 mg Tablet (FAVIR 200)
During these atypical times of COVID-19 Pandemic Crisis, Deurali-Janta is the first National Pharmaceutical Company to attain manufacturing License for FAVIPIRAVIR 200 mg Tablet (FAVIR 200). The drug is the recommended therapy in many countries for mild to moderate cases of COVID-19. FAVIPIRAVIR is the part of COVID-19 treatment protocol approved by NMC (Nepal Medical Council). In the history of Nepal, Deurali-Janta Pharmaceuticals is the first and only company to conduct phase III clinical trial of medicinal product (Favipiravir) in collaboration of NHRS and MoH of Nepal.
Around September 2020, the Department of Drug Administration (DDA) of Nepal approved Favipiravir manufactured by Nepalese-based company- Deurali-Janta Pharmaceuticals Pvt. Ltd., indicated for novel or re-emerging influenza virus infections, and as investigational use for novel coronavirus SARS-CoV-2 infection. Thereafter, Deurali-Janta in collaboration with National Health Research Council (NHRC) begun Nepal’s first ever phase 3 clinical trial of FAVIR 200.
Close